281 related articles for article (PubMed ID: 28584143)
1. Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis.
Srivastava S; Magombedze G; Koeuth T; Sherman C; Pasipanodya JG; Raj P; Wakeland E; Deshpande D; Gumbo T
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584143
[TBL] [Abstract][Full Text] [Related]
2. Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps.
Deshpande D; Srivastava S; Pasipanodya JG; Bush SJ; Nuermberger E; Swaminathan S; Gumbo T
Clin Infect Dis; 2016 Nov; 63(suppl 3):S80-S87. PubMed ID: 27742638
[TBL] [Abstract][Full Text] [Related]
3. Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing.
van Rijn SP; Srivastava S; Wessels MA; van Soolingen D; Alffenaar JC; Gumbo T
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696238
[TBL] [Abstract][Full Text] [Related]
4. Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.
Srivastava S; Deshpande D; Pasipanodya J; Nuermberger E; Swaminathan S; Gumbo T
Clin Infect Dis; 2016 Nov; 63(suppl 3):S102-S109. PubMed ID: 27742641
[TBL] [Abstract][Full Text] [Related]
5. The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis.
Srivastava S; Deshpande D; Nuermberger E; Lee PS; Cirrincione K; Dheda K; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S336-S341. PubMed ID: 30496463
[TBL] [Abstract][Full Text] [Related]
6. Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.
Deshpande D; Pasipanodya JG; Mpagama SG; Bendet P; Srivastava S; Koeuth T; Lee PS; Bhavnani SM; Ambrose PG; Thwaites G; Heysell SK; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S293-S302. PubMed ID: 30496461
[TBL] [Abstract][Full Text] [Related]
7. Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.
Deshpande D; Pasipanodya JG; Srivastava S; Bendet P; Koeuth T; Bhavnani SM; Ambrose PG; Smythe W; McIlleron H; Thwaites G; Gumusboga M; Van Deun A; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S274-S283. PubMed ID: 30496459
[TBL] [Abstract][Full Text] [Related]
8. Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection.
Wasserman S; Denti P; Brust JCM; Abdelwahab M; Hlungulu S; Wiesner L; Norman J; Sirgel FA; Warren RM; Esmail A; Dheda K; Gandhi NR; Meintjes G; Maartens G
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617089
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy.
Brown AN; Drusano GL; Adams JR; Rodriquez JL; Jambunathan K; Baluya DL; Brown DL; Kwara A; Mirsalis JC; Hafner R; Louie A
mBio; 2015 Nov; 6(6):e01741-15. PubMed ID: 26530386
[TBL] [Abstract][Full Text] [Related]
10. Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.
Deshpande D; Srivastava S; Nuermberger E; Pasipanodya JG; Swaminathan S; Gumbo T
Clin Infect Dis; 2016 Nov; 63(suppl 3):S88-S94. PubMed ID: 27742639
[TBL] [Abstract][Full Text] [Related]
11. Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration.
Gumbo T; Sherman CM; Deshpande D; Alffenaar JW; Srivastava S
Int J Infect Dis; 2021 Mar; 104():680-684. PubMed ID: 33556616
[TBL] [Abstract][Full Text] [Related]
12. Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.
Deshpande D; Pasipanodya JG; Mpagama SG; Srivastava S; Bendet P; Koeuth T; Lee PS; Heysell SK; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S317-S326. PubMed ID: 30496457
[TBL] [Abstract][Full Text] [Related]
13. Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.
Gumbo T; Pasipanodya JG; Nuermberger E; Romero K; Hanna D
Clin Infect Dis; 2015 Aug; 61 Suppl 1():S18-24. PubMed ID: 26224768
[TBL] [Abstract][Full Text] [Related]
14. Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation.
Heinrichs MT; Drusano GL; Brown DL; Maynard MS; Sy SKB; Rand KH; Peloquin CA; Louie A; Derendorf H
Int J Antimicrob Agents; 2019 Mar; 53(3):275-283. PubMed ID: 30385322
[TBL] [Abstract][Full Text] [Related]
15. Linezolid as treatment for pulmonary Mycobacterium avium disease.
Deshpande D; Srivastava S; Pasipanodya JG; Gumbo T
J Antimicrob Chemother; 2017 Sep; 72(suppl_2):i24-i29. PubMed ID: 28922806
[TBL] [Abstract][Full Text] [Related]
16. Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis.
Srivastava S; Modongo C; Siyambalapitiyage Dona CW; Pasipanodya JG; Deshpande D; Gumbo T
Antimicrob Agents Chemother; 2016 Oct; 60(10):5922-7. PubMed ID: 27458215
[TBL] [Abstract][Full Text] [Related]
17. Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index.
Wasserman S; Meintjes G; Maartens G
Expert Rev Anti Infect Ther; 2016 Oct; 14(10):901-15. PubMed ID: 27532292
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.
Gumbo T; Dona CS; Meek C; Leff R
Antimicrob Agents Chemother; 2009 Aug; 53(8):3197-204. PubMed ID: 19451303
[TBL] [Abstract][Full Text] [Related]
19. Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease.
Srivastava S; Pasipanodya J; Sherman CM; Meek C; Leff R; Gumbo T
Antimicrob Agents Chemother; 2015 Apr; 59(4):2273-9. PubMed ID: 25645830
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis.
Park IN; Hong SB; Oh YM; Kim MN; Lim CM; Lee SD; Koh Y; Kim WS; Kim DS; Kim WD; Shim TS
J Antimicrob Chemother; 2006 Sep; 58(3):701-4. PubMed ID: 16857689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
